

Pfizer Independent Medical Education Request for Proposals (RFP)

Early Diagnosis Improvement of Chlamydia Infections

Competitive Grant Program – Pfizer Internal Review Process



Overview

This competitive program seeks to support health care professionals medical education to improve early diagnosis of chlamydia infections.



Geographic Scope

Global



Project Types and Area of Interest

Potential applicants are encouraged to develop educational programs to identify and address the educational needs, barriers, and gaps for early diagnosis of chlamydia.

Under this RFP, grants will be offered to support evidence-based programs, with a high reach potential, aiming to improve routine screening practices, appropriate diagnostic methods for chlamydia, use of latest guidelines, and best practices for early diagnosis of chlamydia infections. Educational programs with a focus on addressing specific challenges faced by marginalized populations are also within scope.

Independent medical educational proposals may include live and/or virtual & theoretical and/or practical activities, educational public health interventions, enduring courses, workshops, modules, hands-on-training, educational resources and tools, technology platforms and social media, or any combination of traditional and/or innovative formats.



Key Milestones

- Application submission deadline: October 7, 2024
- Anticipated decision notification date: December 2024
- Anticipated project start date: on or after January 2025



Funding Range and Project Length

Individual projects requesting up to \$100,000 USD will be considered. Pfizer anticipates awarding 2 projects.

Project length will be a maximum of 12 months.

I. Eligibility

Geographic Scope/Location of Project:

- Global, prioritizing cross-regional and international reach

Applicant Eligibility Criteria

- The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; health care institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to health care professional education and/or healthcare improvement.
- Proposals with a coverage of more than 1 country, or with a regional or international reach are highly recommended.
- Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
- The applicant must be the project/program lead or an authorized designee of such individual (e.g., project/program lead's grant coordinator).
- The project/program lead must be an employee or contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.

II. Requirements

Date RFP Issued:

- August 13, 2024

Clinical Area:

- Chlamydia-Anti infectives

General Area of Interest for this RFP:

Chlamydia is one of the most commonly diagnosed sexually transmitted infection (STI) worldwide. Chlamydia often goes undetected due to its asymptomatic nature or symptoms that can often go initially unnoticed. This leads to the ongoing transmission of the infection, increased risk of serious complications, and substantial healthcare costs. Timely detection of chlamydia infections has an important factor to minimize the impact of chlamydia on individuals and communities.

This RFP aims to support comprehensive medical education programs focused on early diagnosis of chlamydia infections. Pfizer will support the following proposals in scope below:

- Programs aiming to provide support to healthcare professionals (HCPs) in identifying and addressing the educational needs, barriers, and gaps related to early diagnosis of chlamydia; improve HCPs' knowledge

on the importance of routine screening, proper pathogen identification, and the use of appropriate diagnostic methods for chlamydia infections.

- Programs developing evidence-based educational methods, with the inclusion of experts in the field, use of latest guidelines and best practices for chlamydia diagnosis, and emphasis on the importance of early detection.
- Programs implementing partnerships with local, regional, national, or international organizations with high reach to impact HCPs and individuals at risk.

Independent Medical Education proposals may include live and/or virtual & theoretical and/or practical activities, educational public health interventions, enduring courses, workshops, modules, hands-on-training, educational resources and tools, technology platforms and social media, or any combination of traditional and/or innovative formats.

There is a considerable disparity in the rates of chlamydia infection between different populations. Certain demographic groups are particularly vulnerable to chlamydia. This health gap stems from various factors, including insufficient access to sexual health education, limited preventive measures, and inadequate healthcare services in certain communities. This RFP will also prioritize projects aiming to address disparity gaps and the burden of chlamydia in disproportionately affected marginalized populations. In scope:

- Projects aiming to enhance healthcare professionals' knowledge and skills regarding the early diagnosis of chlamydia infections in underserved and underrepresented populations, incorporating educational strategies to address health disparities and promote health equity.
- Evidence-based curricula that address the knowledge gap and unique challenges faced by underserved communities, including cultural, socioeconomic, and access-related barriers to care with the aim to reduce the burden of chlamydia infections and improve health outcomes within these populations.

Successful proposals should include measurement of outcomes, inclusive of learner progression throughout the activity, extent to which the activity closed the identified gaps, and patient impact. Preferred proposals would also provide learners with continuing medical education (CME) accreditation.

It is not our intent to support clinical research or quality improvement projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Target Audience:

Primary care providers, nurses, public health professionals, community health workers, obstetrics and gynecology specialists, urologists, ID specialists, venereologists and other healthcare professionals involved in the testing, diagnosis, and treatment of patients with sexually-transmitted infections, including chlamydia.

Expected Approximate Monetary Range of Grant Applications:

- Individual projects requesting up to \$100,000 USD will be considered. The estimated total available budget related to this RFP is \$200,000 USD.
- Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.

Key Dates:

- RFP release date: August 13, 2024
- Grant Application due date: October 7, 2024
Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
- Anticipated Grant Award Notification Date: December 2024
Grants will be distributed following a fully executed agreement.
- Anticipated Project Start and End Date: on or after January 2025 to December 2025

How to Submit:

Note: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.

- Please go to www.cybergrants.com/pfizer/knowledge and sign in. First-time users should click “Create your password”. [Note: there are individual portals for each grant application type. Please be sure to use the URL above.]
- Click the “Start A New Knowledge Gap Application” button.
- In the application:
 - For the question “What type of request are you submitting?” select **Response to a Request for Proposal (RFP)**
 - For the question “Are you replying to a Request for Proposal (RFP) as part of the Competitive Grant Program?” select **Yes**
 - Select the following Competitive Grant Program Name: **2024 HOS Global Early Diagnosis Improvement of Chlamydia Infections IME**
 - Select the following Primary Area of Interest: **Infectious Disease – Bacterial - KG**
- Requirements for submission:
Complete all required sections of the online application and upload your project proposal (see [Appendix](#)) in the General RFP Submission field.
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.

IMPORTANT: Be advised applications submitted after the due date will not be reviewed.

Questions:

- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Talita Honorato-Rzeszewicz at Talita.honorato-rzeszewicz@pfizer.com with the subject line: 2024 HOS Global Early Diagnosis Improvement of Chlamydia Infections IME.

Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click [here](#) to view the core terms of the agreement.
- Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicant is encouraged to share the core terms with counsel for approval prior to submitting an application.
- Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the grantee organization.

- This RFP is supported by Pfizer Inc. and, if approved, payment will be sent from the United States.

Review and Approval Process:

- Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.

Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

About Pfizer Global Medical Grants & Partnerships

Pfizer Global Medical Grants & Partnerships (GMGP) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMGP competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

Appendix

General RFP Submission Requirements

Applications will be accepted via the online portal listed in the [How to Submit](#) section. Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. When uploading your Project Proposal please ensure it addresses the following sections:

Goals and Objectives

- Briefly state the overall goal of the project.
- List the objectives you plan to meet with your project, in terms of learning and expected outcomes.

Needs Assessment for the Project

- Include a description of your organization's needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.

Target Audience

- Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.

Project Design and Methods

- Describe the planned project, the educational approach, and the way the planned methods address the established need.

Innovation

- Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions.

Evaluation and Outcomes

- In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.

Dissemination Plan

- Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.

Feasibility, Potential Challenges, and Contingency Plan

- Assess the feasibility of the project including accessibility to educational resources, institutional capacity and personnel expertise, target audience reach/ engagement strategy, and dissemination plan.

- Describe the possible obstacles that could hinder the successful implementation and execution of the educational project, including logistical constraints, technical limitations, and any barriers that may delay project implementation or impede the participation of both personnel and participants.
- In the event of anticipated potential setbacks, outline a risk management plan and propose alternative adjustments to guarantee the successful completion of the project.

Anticipated Project Timeline

- Provide an anticipated timeline for your project including project start/end dates.

Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.

Organization Detail

- Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project.

Budget Detail

- Please submit your budget in USD.
- Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application.
- While estimating your budget please keep the following items in mind:
 - Independent Medical Education Grants awarded by GMG cannot be used to purchase therapeutic assets (prescription or non-prescription).
 - Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer. Please [click here](#) for details. General organizational running costs such as legal fees, insurance, heating, and lighting etc. should be included in an Institutional Overhead (if required). These costs are not specific to a grant request and therefore, should not appear as line items in budgets. However, costs that are specific to the study (e.g., some countries require insurance to be taken out on a per-study basis for clinical research) would be acceptable to be included as line items.